Zhejiang Huakang Pharmaceutical Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Deshui Chen
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | 15.9% |
| Management average tenure | no data |
| Board average tenure | no data |
Recent management updates
Recent updates
A Look At The Fair Value Of Zhejiang Huakang Pharmaceutical Co., Ltd. (SHSE:605077)
Dec 19
Zhejiang Huakang Pharmaceutical's (SHSE:605077) Anemic Earnings Might Be Worse Than You Think
Nov 02Zhejiang Huakang Pharmaceutical Co., Ltd.'s (SHSE:605077) Earnings Are Not Doing Enough For Some Investors
Oct 14Zhejiang Huakang Pharmaceutical (SHSE:605077) Will Want To Turn Around Its Return Trends
Sep 26Improved Earnings Required Before Zhejiang Huakang Pharmaceutical Co., Ltd. (SHSE:605077) Shares Find Their Feet
Jul 02Zhejiang Huakang Pharmaceutical (SHSE:605077) May Have Issues Allocating Its Capital
May 28We Think That There Are Some Issues For Zhejiang Huakang Pharmaceutical (SHSE:605077) Beyond Its Promising Earnings
May 02CEO
Deshui Chen (55 yo)
no data
Tenure
CN¥1,505,800
Compensation
Mr. Deshui Chen is Non-Executive Director of Zhejiang Kaihua Rural Commercial Bank Company Limited. He is Chairman of the Board & GM of Zhejiang Huakang Pharmaceutical Co. Ltd.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 13:54 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zhejiang Huakang Pharmaceutical Co., Ltd. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Citic Securities Co., Ltd. |
| Zhe Wang | Citic Securities Co., Ltd. |